Clinical Trial Update: A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating AK104 in combination with Lenvatinib and transarterial chemoembolization (TACE) for unresectable, non-metastatic hepatocell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Akeso | Conditions: Unresectable, Non-metastatic Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING